Promisingly, blocking TGF-B1/B2 enhances sensitivity to combination chemotherapy in PDAC [6], and silencing TGF-B2 expression inhibits tumour proliferation in PDAC cell lines [7] and can boost gemcitabine chemosensitivity [8]. The gene discussed is TGFB1; the disease is neoplasm.